Experimental Hematology
Volume 37, Issue 7 , Pages 838-848 , July 2009

Defective γδ T-cell function and granzyme B gene polymorphism in a cohort of newly diagnosed breast cancer patients

  • Ameera Gaafar

      Affiliations

    • Histocompatibility and Immunogenetics, Riyadh, Saudi Arabia
    • ,
  • Mahmoud Deeb Aljurf

      Affiliations

    • King Faisal Cancer Center, Riyadh, Saudi Arabia
    • ,
  • Abdullah Al-Sulaiman

      Affiliations

    • Histocompatibility and Immunogenetics, Riyadh, Saudi Arabia
    • ,
  • Alia Iqniebi

      Affiliations

    • Histocompatibility and Immunogenetics, Riyadh, Saudi Arabia
    • ,
  • Pulicat S. Manogaran

      Affiliations

    • Flow Cytometry, Stem Cell Therapy Program, Riyadh, Saudi Arabia
    • ,
  • Gamal Eldin H. Mohamed

      Affiliations

    • Department of Biostatistics, Epidemiology, and Scientific Computing, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia
    • ,
  • Adher Al-Sayed

      Affiliations

    • King Faisal Cancer Center, Riyadh, Saudi Arabia
    • ,
  • Hazaa Alzahrani

      Affiliations

    • King Faisal Cancer Center, Riyadh, Saudi Arabia
    • ,
  • Fahad Alsharif

      Affiliations

    • King Faisal Cancer Center, Riyadh, Saudi Arabia
    • ,
  • Fahad Mohareb

      Affiliations

    • King Faisal Cancer Center, Riyadh, Saudi Arabia
    • ,
  • Dahish Ajarim

      Affiliations

    • King Faisal Cancer Center, Riyadh, Saudi Arabia
    • ,
  • Abdelghani Tabakhi

      Affiliations

    • Department of Pathology and Laboratory Medicine, Riyadh, Saudi Arabia
    • ,
  • Khalid Al-Hussein

      Affiliations

    • Histocompatibility and Immunogenetics, Riyadh, Saudi Arabia
    • Corresponding Author InformationOffprint requests to: Khaled Al-Hussein, Ph.D., Histocompatibility and Immunogenetics Research Unit, Stem Cell Therapy Program, King Faisal Specialist Hospital and Research Center, P.O. Box 3354, Riyadh 11211, Saudi Arabia

Received 26 March 2008 ,Revised 9 March 2009 ,Accepted 14 April 2009.

References 

  1. Aljurf M, Ezzat A, Omusa M. Emerging role of γδ T-cells in health and disease. Blood Rev. 2002;16:203–206
  2. Doherty PC. The function of γδ T cells. Br J Haematol. 1992;81:321–324
  3. Modlin RL, Pirmez C, Hofman FM, et al. Lymphocytes bearing antigen-specific γδ T-cell receptors accumulate in human infectious disease lesions. Nature. 1989;339:544–548
  4. Smyth MJ, Godfrey DI, Trapani JA. A fresh look at tumor immunosurveillance and immunotherapy. Nat Immunol. 2001;2:293–299
  5. Girardi M. Immunosurveillance and immunoregulation by γδ T cells. J Invest Dermatol. 2006;126:25–31
  6. Ensslin AS, Formby B. Comparison of cytolytic and proliferative activities of human γδ and αβ T cells from peripheral blood against various human tumor cell lines. J Natl Cancer Inst. 1991;83:1564–1569
  7. Kunzmann V, Wilhelm M. Anti-lymphoma effect of γδ T cells. Leuk Lymphoma. 2005;46:671–680
  8. Dolstra H, Preijers F, Van de Wiel-van Kemenade E, Schattenberg A, Galama J, de Witte T. Expansion of CD8 + CD57 + T cells after allogeneic BMT is related with a low incidence of relapse and with cytomegalovirus infection. Br J Haematol. 1995;90:300–307
  9. Duval M, Yotnda P, Bensussan A, et al. Potential antileukemic effect of γδ T cells in acute lymphoblastic leukemia. Leukemia. 1995;9:863–868
  10. Kunzmann V, Bauer E, Feurle J, Weissinger F, Tony HP, Wilhelm M. Stimulation of γδ T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma. [see comment] Blood. 2000;96:384–392
  11. Sicard H, Al Saati T, Delsol G, Fournie JJ. Synthetic phosphoantigens enhance human Vγ9Vδ2 T lymphocytes killing of non-Hodgkin's B lymphoma. Mol Med. 2001;7:711–722
  12. Girardi M, Oppenheim DE, Steele CR, et al. Regulation of cutaneous malignancy by γδ T cells. [see comment] Science. 2001;294:605–609
  13. Smyth MJ, Thia KY, Street SE, et al. Differential tumor surveillance by natural killer (NK) and NKT cells. J Exp Med. 2000;191:661–668
  14. Kato Y, Tanaka Y, Tanaka H, Yamashita S, Minato N. Requirement of species-specific interactions for the activation of human γδ T cells by pamidronate. J Immunol. 2003;170:3608–3613
  15. Kabelitz D, Wesch D, Pitters E, Zoller M. Potential of human γδ T lymphocytes for immunotherapy of cancer. Int J Cancer. 2004;112:727–732
  16. Dieli F, Gebbia N, Poccia F, et al. Induction of γδ T-lymphocyte effector functions by bisphosphonate zoledronic acid in cancer patients in vivo. Blood. 2003;102:2310–2311
  17. Dieli F, Poccia F, Lipp M, et al. Differentiation of effector/memory Vδ2 T cells and migratory routes in lymph nodes or inflammatory sites. J Exp Med. 2003;198:391–397
  18. Wilhelm M, Kunzmann V, Eckstein S, et al. γδ T cells for immune therapy of patients with lymphoid malignancies. Blood. 2003;102:200–206
  19. Mariani S, Muraro M, Pantaleoni F, et al. Effector γδ T cells and tumor cells as immune targets of zoledronic acid in multiple myeloma. Leukemia. 2005;19:664–670
  20. Gutierrez LS, Eliza M, Niven-Fairchild T, Naftolin F, Mor G. The Fas/Fas-ligand system: a mechanism for immune evasion in human breast carcinomas. Breast Cancer Res Treat. 1999;245–253
  21. Brenner BG, McCrea EL, Margolese RG. Cytolysis of mammary tumor targets by resting, interleukin-2 stimulated and in vitro cultured peripheral blood lymphocytes from breast cancer patients. Anticancer Res. 1988;8:653–658
  22. Gao Y, Yang W, Pan M, et al. γδ T cells provide an early source of interferon gamma in tumor immunity. J Exp Med. 2003;198:433–442
  23. Johnstone RW, Cretney E, Smyth MJ. P-glycoprotein protects leukemia cells against caspase-dependent, but not caspase-independent, cell death. Blood. 1999;93:1075–1085
  24. Shtil AA, Turner JG, Dalton WS, Yu H. Alternative pathways of cell death to circumvent pleiotropic resistance in myeloma cells: role of cytotoxic T-lymphocytes. Leuk Lymphoma. 2000;38:59–70
  25. McIlroy D, Cartron PF, Tuffery P, et al. A triple-mutated allele of granzyme B incapable of inducing apoptosis. Proc Natl Acad Sci U S A. 2003;100:2562–2567
  26. Gaafar A, Veress B, Permin H, Kharazmi A, Theander TG, el Hassan AM. Characterization of the local and systemic immune responses in patients with cutaneous leishmaniasis due to Leishmania major. Clin Immunol. 1999;91:314–320
  27. Han D, Xu X, Baidal D, et al. Assessment of cytotoxic lymphocyte gene expression in the peripheral blood of human islet allograft recipients: elevation precedes clinical evidence of rejection. Diabetes. 2004;53:2281–2290
  28. Campbell MJ, Gardner MJ. Calculating confidence intervals for some non-parametric analyses. Br Med J (Clin Res Ed.). 1988;296:1454–1456
  29. Diehl S, Anguita J, Hoffmeyer A, et al. Inhibition of Th1 differentiation by IL-6 is mediated by SOCS1. Immunity. 2000;13:805–815
  30. Kunzmann V, Bauer E, Wilhelm M. Gamma/delta T-cell stimulation by pamidronate. N Engl J Med. 1999;340:737–738
  31. Alam SM, Clark JS, Leech V, Whitford P, George WD, Campbell AM. T cell receptor gamma/delta expression on lymphocytes populations of breast cancer patients. Immunol Lett. 1992;31:279–283
  32. Fujimiya Y, Suzuki Y, Katakura R, et al. In vitro interleukin 12 activation of peripheral blood CD3(+)CD56(+) and CD3(+)CD56(-) γδ T cells from glioblastoma patients. Clin Cancer Res. 1997;3:633–643
  33. Alexander AA, Maniar A, Cummings JS, et al. Isopentenyl pyrophosphate-activated CD56 + γδ T lymphocytes display potent antitumor activity toward human squamous cell carcinoma. Clin Cancer Res. 2008;14:4232–4240
  34. Crowe NY, Smyth MJ, Godfrey DI. A critical role for natural killer T cells in immunosurveillance of methylcholanthrene-induced sarcomas. J Exp Med. 2002;196:119–127
  35. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. [see comment] Nat Immunol. 2002;3:991–998
  36. Sato K, Kimura S, Segawa H, et al. Cytotoxic effects of γδ T cells expanded ex vivo by a third generation bisphosphonate for cancer immunotherapy. Int J Cancer. 2005;116:94–99
  37. Darmon AJ, Nicholson DW, Bleackley RC. Activation of the apoptotic protease CPP32 by cytotoxic T-cell-derived granzyme B. Nature. 1995;377:446–448
  38. Mullbacher A, Waring P, Tha Hla R, et al. Granzymes are the essential downstream effector molecules for the control of primary virus infections by cytolytic leukocytes. Proc Natl Acad Sci U S A. 1999;96:13950–13955
  39. Pascoe MD, Marshall SE, Welsh KI, Fulton LM, Hughes DA. Increased accuracy of renal allograft rejection diagnosis using combined perforin, granzyme B, and Fas ligand fine-needle aspiration immunocytology. Transplantation. 2000;69:2547–2553
  40. Li B, Hartono C, Ding R, et al. Noninvasive diagnosis of renal-allograft rejection by measurement of messenger RNA for perforin and granzyme B in urine. [see comment] N Engl J Med. 2001;344:947–954
  41. Shtil AA, Turner JG, Durfee J, Dalton WS, Yu H. Cytokine-based tumor cell vaccine is equally effective against parental and isogenic multidrug-resistant myeloma cells: the role of cytotoxic T lymphocytes. Blood. 1999;93:1831–1837
  42. Zaitsu M, Yamamoto K, Ishii E, et al. High frequency of QPY allele and linkage disequilibrium of granzyme-B in Epstein-Barr-virus-associated hemophagocytic lymphohistiocytosis. Tissue Antigens. 2004;64:611–615

PII: S0301-472X(09)00131-3

doi: 10.1016/j.exphem.2009.04.003

Experimental Hematology
Volume 37, Issue 7 , Pages 838-848 , July 2009

Article Tools

* Image Usage & Resolution